Clinical trial · Observational
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study
Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study (MULTIPLI-0)
NCT03546127CI-TRIAL-00094922MULTIPLI-0completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Next Generation Sequencing in cancer: a feasibility study in France to assess sample circuit and to perform analyzes within a limited time.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Carcinoma | Colorectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Soft Tissue Sarcoma | Soft Tissue Sarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next Generation Sequencing (NGS): exome, RNA seq | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- STS
- description
- Patients with advanced/metastatic soft-tissue sarcoma
- interventionNames
- Genetic: Next Generation Sequencing (NGS): exome, RNA seq
- label
- CCR
- description
- Patients with metastatic colorectal carcinoma
- interventionNames
- Genetic: Next Generation Sequencing (NGS): exome, RNA seq
Primary outcomes (1)
- measure
- Delay time to send a validated exome sequencing report from sample receipt
- timeFrame
- an average of 6 weeks
- description
- The time delay between the date of sample receipt by the platform and the date of dispatch of a validated MTB report to physician
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients * Disease: Advanced and/or metastatic soft-tissue sarcoma OR metastatic carcinoma * Patient consenting to tumor sequencing, secondary reuse of their data * Patient informed about this study Exclusion Criteria: * N/A
References
Publications (1)
- RESULTFGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Sante); Auzanneau C, Bacq D, Bellera C, Blons H, Boland A, Boucheix M, Bourdon A, Chollet E, Chomienne C, Deleuze JF, Delmas C, Dinart D, Esperou H, Geillon F, Geneste D, Italiano A, Jean D, Khalifa E, Laizet Y, Laurent-Puig P, Lethimonnier F, Levy-Marchal C, Lucchesi C, Malle C, Mancini P, Mathoulin-Pelissier S, Meyer V, Marie-Ange P, Perkins G, Sellan-Albert S, Soubeyran I, Wallet C. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan. ESMO Open. 2020 Jul;5(4):e000744. doi: 10.1136/esmoopen-2020-000744. PMID 32713836